ExpressCells
PrivateLast Round
Series A
Extension
Apr 1, 2021
Total Funding Raised
$1.49M
Company Overview
ExpressCells operates in Healthcare & Life Sciences and is based in Philadelphia, Pennsylvania. Its latest recorded funding round was a Series A Extension round in April 2021.
ExpressCells is a biotechnology company that develops medical biotechnologies designed to create custom cell lines for biological research.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ExpressCells Comparables
Compare ExpressCells with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Demeetra AgBio | 81% | |
| iXCells Biotechnologies | 81% | |
| Creative Biogene | 80% |
For institutional investors. Book with your work email.
ExpressCells Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Apr 1, 2021 | ||||
| Series A | Jul 1, 2019 |
For institutional investors. Book with your work email.
ExpressCells Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Benjamin Franklin Technology Partners | Grant, Series A Extension |
| MIT Alumni Angels of Northern California | Series A Extension |
| Rowan Innovation Venture Fund | Series A |
| TCA Venture Group | Series A Extension |
| Berkeley Angel Network | Series A Extension |
| Keiretsu Forum Mid-Atlantic | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 1, 2021
$591K round with participation from Benjamin Franklin Technology Partners.
- Jul 1, 2019
$800K round led by Keiretsu Forum Mid-Atlantic and Rowan Innovation Venture Fund.
For institutional investors. Book with your work email.
ExpressCells Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ExpressCells's valuation, stock price, and market status.
Is ExpressCells a public or private company?
ExpressCells is a private company.
What is the current stock price of ExpressCells?
ExpressCells is a private company, so its shares have no public market price. Caplight tracks ExpressCells's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ExpressCells worth (valuation)?
Valuation information for ExpressCells is not publicly available.
Can I buy ExpressCells stock?
ExpressCells shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ExpressCells's last funding round?
ExpressCells's most recent funding round was Series A Extension on April 1, 2021.
Who are the main investors in ExpressCells?
Key investors in ExpressCells include Rowan Innovation Venture Fund, Keiretsu Forum Mid-Atlantic.
Will ExpressCells IPO soon?
No public IPO plans have been announced for ExpressCells.
How can I track ExpressCells secondary market activity?
Caplight tracks bids, offers, and trades in ExpressCells's shares on secondary markets.